Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · IEX Real-Time Price · USD
6.47
+0.07 (1.09%)
At close: Jul 2, 2024, 4:00 PM
6.56
+0.09 (1.39%)
After-hours: Jul 2, 2024, 7:22 PM EDT
Relay Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Relay Therapeutics stock have an average target of 22.8, with a low estimate of 15 and a high estimate of 30. The average target predicts an increase of 252.40% from the current stock price of 6.47.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for RLAY stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 2 | 2 |
Buy | 3 | 3 | 3 | 3 | 3 | 3 |
Hold | 2 | 2 | 2 | 2 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 8 | 8 | 8 | 8 | 5 | 5 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +209.12% | Jun 7, 2024 |
Barclays | Barclays | Hold → Buy Upgrades $15 | Hold → Buy | Upgrades | $15 | +131.84% | May 10, 2024 |
JMP Securities | JMP Securities | Buy Reiterates $24 | Buy | Reiterates | $24 | +270.94% | May 6, 2024 |
Oppenheimer | Oppenheimer | Buy Reiterates $33 → $25 | Buy | Reiterates | $33 → $25 | +286.40% | May 6, 2024 |
Stifel | Stifel | Strong Buy Maintains $25 → $30 | Strong Buy | Maintains | $25 → $30 | +363.68% | Feb 22, 2024 |
Financial Forecast
Revenue This Year
10.44M
from 25.55M
Decreased by -59.15%
Revenue Next Year
7.53M
from 10.44M
Decreased by -27.85%
EPS This Year
-2.88
from -2.79
EPS Next Year
-2.93
from -2.88
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 12.1M | 69.9M | 82.1M | 97.7M | 209.5M |
Avg | 10.4M | 7.5M | 23.1M | 48.1M | 141.9M |
Low | 9.8M | n/a | n/a | 10.8M | 63.7M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -52.7% | 569.4% | 990.4% | 322.2% | 335.6% |
Avg | -59.1% | -27.8% | 207.1% | 107.9% | 195.1% |
Low | -61.6% | - | - | -53.4% | 32.5% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -2.87 | -2.55 | -1.97 | -1.76 | -1.05 |
Avg | -2.88 | -2.93 | -2.66 | -2.39 | -1.90 |
Low | -2.97 | -3.36 | -3.17 | -3.12 | -2.67 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.